查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2052203

非專利抗癌藥物市場：市場洞察、競爭格局及市場預測（2033 年）

Generic Oncology Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 199 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

隨著醫療專業人員日益關注價格合理且易於取得的癌症治療方法，非專利抗癌藥物市場在全球正獲得顯著成長。癌症患者數量的增加、醫療成本的飆升以及品牌抗癌藥物專利到期是推動市場擴張的關鍵因素。非專利抗癌藥物在已開發市場和新興市場都獲得了廣泛認可，因為它們在保持療效的同時，也提供了一種經濟有效的治療選擇。 2026年，全球非專利抗癌藥物市場規模為281億美元，預計2033年將達434億美元，預測期內年複合成長率（CAGR）為6.40%。

受早期癌症診斷和治療意識提高以及政府對學名藥支持力度加大的推動，市場成長正在進一步加速。製藥公司也在拓展抗癌產品平臺，以鞏固市場佔有率並滿足日益成長的全球需求。

市場洞察

隨著價格較低廉的品牌抗癌藥物替代品的出現，市場正經歷穩定成長。非專利抗癌藥物廣泛用於治療乳癌、肺癌、血癌、大腸癌以及許多其他惡性腫瘤。隨著醫療保健系統不斷優先考慮成本最佳化，學名藥正成為全球癌症治療策略的重要組成部分。

口服抗癌藥物的廣泛應用正在改變治療方式，提高了患者的便利性，並減少了對長期住院的依賴。同時，醫院藥局和線上藥局平台正在多個地區提高學名藥的可及性。

為了在瞬息萬變的醫藥產業中保持競爭力，製藥公司正致力於提高生產效率、強化供應鏈並推出高品質製劑。加快學名藥核准的監管支持也大大促進了市場擴張。

促進因素

非專利抗癌藥物市場發展的主要動力是全球癌症發生率的不斷上升。人口老化、不健康的生活方式、吸煙習慣以及環境因素都導致了癌症診斷率的上升，進而引發了對價格合理的治療方案日益成長的需求。

多種品牌抗癌藥物專利到期為非專利藥生產商帶來了機會。隨著專利到期，製藥公司可以推出價格更低廉的高需求癌症治療藥物學名藥，從而提高患者的用藥可及性並降低整體治療成本。

政府推廣使用學名藥的措施也促進了市場成長。許多國家正在實施旨在降低醫療成本和改善癌症基本治療可近性的政策。此外，開發中國家醫療基礎設施的擴建也改善了癌症治療設施和藥物的可近性。

製藥生產技術的進步使企業能夠生產出療效和安全性更高的優質學名藥。隨著生物類似抗癌藥物的不斷研發，預計未來幾年市場機會將進一步擴大。

商業機會

非專利抗癌藥物市場為製藥企業和相關人員提供了巨大的成長潛力。新興市場由於醫療保健投資的增加、癌症防治意識的提高以及醫療基礎設施的改善，盈利尤其可觀。

各公司正加大研發投入，以拓展產品系列，以獲得競爭優勢。生物相似藥和高分子學名藥的開發有望創造新的商機，尤其是在標靶癌症治療和生物製藥領域。

數位醫療的擴張和線上藥局的快速發展也為抗癌藥物生產商開闢了新的分銷管道。線上藥局平台正在改善偏遠地區和醫療資源匱乏地區患者取得藥物的途徑，從而有助於提高市場滲透率。

策略聯盟、夥伴關係和收購仍然是領先企業至關重要的成長策略。許多公司正在建立夥伴關係，以增強其製造能力、改善其分銷網路並加速其產品在國際市場的商業化進程。

區域分析

北美地區憑藉其高癌症發病率、完善的醫療保健基礎設施和廣泛的學名藥供應，在非專利抗癌藥物市場佔據主導地位。此外，該地區還受益於優惠的醫保報銷政策以及眾多專注於抗癌藥物研發的大型製藥企業的存在。

歐洲仍然是一個重要的市場，這得益於不斷加強的醫療成本控制措施和對學名藥推廣的有力監管支持。德國、法國和英國等國繼續鼓勵在其公共醫療體系中使用學名藥。

預計亞太地區將在預測期內實現最快成長。癌症發病率上升、醫療基礎設施不斷完善以及印度和中國等國製藥業活動日益活躍，正在推動該地區市場擴張。各國政府為提高癌症治療的可近性所採取的各項舉措，也為市場進一步成長提供了支持。

在拉丁美洲、中東和非洲，由於醫療保健服務的可近性提高以及人們對癌症治療方案的認知度增強，市場呈現穩定發展態勢。預計全部區域對醫療保健現代化投入的增加將創造更多成長機會。

大公司

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz Group AG
  • Mylan NV (Viatris)
  • Biocon
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Lupin Pharmaceuticals
  • Zydus Cadila

分割

按分子

  • 聚合物
  • 低分子

透過行政途徑

  • 口服
  • 腸外

按銷售管道

  • 零售藥房
  • 醫院藥房
  • 網路藥房

按地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

目錄

第1章執行摘要

第2章 市場概覽

  • 市場定義與細分
  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機遇
  • 價值鏈分析
  • 新冠疫情影響分析
  • 波特五力分析
  • 俄烏衝突的影響
  • PESTLE分析
  • 監管分析
  • 價格趨勢分析
    • 當前價格及未來預測（2025-2033）
    • 價格影響因素

第3章：2020-2033年全球非專利抗癌藥物市場展望

  • 全球非專利抗癌藥物市場展望（按分子類型和價值，單位：十億美元），2020-2033年
    • 聚合物
    • 低分子
  • 全球非專利抗癌藥物市場展望（按給藥途徑分類，價值單位：十億美元），2020-2033年
    • 口服
    • 腸外
  • 全球非專利抗癌藥物市場展望（按分銷管道分類，價值單位：十億美元），2020-2033年
    • 零售藥房
    • 醫院藥房
    • 網路藥房
  • 全球非專利抗癌藥物市場展望（按地區和價值計，單位：十億美元），2020-2033年
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第4章：2020-2033年北美非專利抗癌藥物市場展望

第5章：2020-2033年歐洲非專利抗癌藥物市場展望

第6章：2020-2033年亞太地區非專利抗癌藥物市場展望

第7章：2020-2033年拉丁美洲非專利抗癌藥物市場展望

第8章：2020-2033年中東和非洲非專利抗癌藥物市場展望

第9章 競爭情勢

  • 公司與細分市場熱圖
  • 2025年各公司市佔率分析
  • 競爭對手儀錶板
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz Group AG
    • Mylan NV (Viatris)
    • Biocon
    • Sun Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals
    • Fresenius Kabi AG
    • Pfizer Inc.
    • Lupin Pharmaceuticals
    • Zydus Cadila

第10章附錄

簡介目錄

The Generic Oncology Drugs Market is gaining substantial momentum worldwide as healthcare providers increasingly focus on affordable and accessible cancer therapies. The growing burden of cancer cases, rising healthcare expenditures, and the expiration of patents for branded oncology drugs are major factors supporting market expansion. Generic oncology medications offer cost-effective treatment alternatives while maintaining therapeutic effectiveness, making them highly preferred across both developed and emerging healthcare markets. The global Generic Oncology Drugs Market is valued at US$ 28.1 Bn in 2026 and is projected to reach US$ 43.4 Bn by 2033, growing at a CAGR of 6.40% during the forecast period.

Increasing awareness regarding early cancer diagnosis and treatment, along with supportive government initiatives promoting generic medicines, is further accelerating market growth. Pharmaceutical manufacturers are also expanding their oncology product pipelines to strengthen market presence and meet rising global demand.

Market Insights

The market is experiencing consistent growth due to the increasing availability of low-cost alternatives to branded cancer therapies. Generic oncology drugs are extensively used in the treatment of breast cancer, lung cancer, blood cancer, colorectal cancer, and several other malignancies. As healthcare systems continue to prioritize cost optimization, generic medicines are becoming a vital component of cancer care strategies worldwide.

The growing adoption of oral oncology medications is reshaping treatment delivery by improving convenience for patients and reducing dependency on prolonged hospital stays. In parallel, hospital pharmacies and online pharmacy platforms are enhancing the accessibility of oncology generics across multiple regions.

Manufacturers are focusing on improving production efficiency, strengthening supply chains, and introducing high-quality formulations to remain competitive in the evolving pharmaceutical landscape. Regulatory support for faster approvals of generic medicines is also contributing significantly to market expansion.

Drivers

A major factor driving the Generic Oncology Drugs Market is the increasing prevalence of cancer globally. Aging populations, unhealthy lifestyles, smoking habits, and environmental factors are contributing to the rising number of cancer diagnoses, thereby increasing the demand for affordable treatment solutions.

Patent expirations of several branded oncology drugs are creating favorable opportunities for generic manufacturers. As patents expire, pharmaceutical companies can launch cost-effective versions of high-demand cancer therapies, enabling wider patient access and reducing overall treatment costs.

Government initiatives promoting the use of generic medicines are also supporting market growth. Many countries are implementing policies aimed at lowering healthcare spending and improving access to essential oncology drugs. In addition, expanding healthcare infrastructure in developing economies is enabling better access to cancer treatment facilities and pharmaceutical products.

Advancements in pharmaceutical manufacturing technologies are helping companies produce high-quality generic drugs with enhanced efficacy and safety standards. The increasing development of biosimilar oncology products is expected to further strengthen market opportunities in the coming years.

Business Opportunity

The Generic Oncology Drugs Market offers strong growth potential for pharmaceutical manufacturers and healthcare stakeholders. Emerging economies represent highly lucrative markets due to rising healthcare investments, growing cancer awareness, and improving medical infrastructure.

Companies are increasingly investing in research and development activities to expand their oncology drug portfolios and gain competitive advantages. The development of biosimilars and large molecule generics is expected to create new business opportunities, particularly in targeted cancer therapies and biologics.

Digital healthcare expansion and the rapid growth of online pharmacies are also opening new distribution opportunities for oncology drug manufacturers. E-pharmacy platforms are improving medication accessibility for patients in remote and underserved areas, contributing to broader market penetration.

Strategic collaborations, partnerships, and acquisitions remain important growth strategies among leading pharmaceutical companies. Many firms are entering partnerships to strengthen manufacturing capabilities, improve distribution networks, and accelerate product commercialization across international markets.

Region Analysis

North America dominates the Generic Oncology Drugs Market due to the high prevalence of cancer, strong healthcare infrastructure, and widespread adoption of generic medicines. The region also benefits from favorable reimbursement policies and the presence of major pharmaceutical companies focused on oncology drug development.

Europe remains a significant market supported by increasing healthcare cost containment measures and strong regulatory support for generic drug adoption. Countries including Germany, France, and the United Kingdom continue to encourage the use of generic medicines within public healthcare systems.

Asia Pacific is expected to register the fastest growth during the forecast period. Rising cancer incidence, expanding healthcare infrastructure, and increasing pharmaceutical manufacturing activities in countries such as India and China are driving regional market expansion. Government initiatives aimed at improving access to affordable cancer treatment are further supporting growth.

Latin America and the Middle East & Africa are also witnessing steady market development due to improving healthcare accessibility and rising awareness regarding cancer treatment options. Increasing investments in healthcare modernization are expected to create additional growth opportunities across these regions.

Key Players

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz Group AG
  • Mylan N.V. (Viatris)
  • Biocon
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Lupin Pharmaceuticals
  • Zydus Cadila

Segmentation

By Molecule

  • Large Molecule
  • Small Molecule

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Generic Oncology Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 3.1. Global Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 3.1.1. Large Molecule
    • 3.1.2. Small Molecule
  • 3.2. Global Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.2.1. Oral
    • 3.2.2. Parenteral
  • 3.3. Global Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.3.1. Retail Pharmacies
    • 3.3.2. Hospital Pharmacies
    • 3.3.3. Online Pharmacies
  • 3.4. Global Generic Oncology Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 4.1. North America Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 4.1.1. Large Molecule
    • 4.1.2. Small Molecule
  • 4.2. North America Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.2.1. Oral
    • 4.2.2. Parenteral
  • 4.3. North America Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.3.1. Retail Pharmacies
    • 4.3.2. Hospital Pharmacies
    • 4.3.3. Online Pharmacies
  • 4.4. North America Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 4.4.2. U.S. Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 4.4.3. U.S. Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 4.4.4. Canada Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 4.4.5. Canada Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 4.4.6. Canada Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 5.1. Europe Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 5.1.1. Large Molecule
    • 5.1.2. Small Molecule
  • 5.2. Europe Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Europe Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.3.1. Retail Pharmacies
    • 5.3.2. Hospital Pharmacies
    • 5.3.3. Online Pharmacies
  • 5.4. Europe Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.2. Germany Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.3. Germany Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.4. Italy Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.5. Italy Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.6. Italy Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.7. France Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.8. France Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.9. France Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.10. U.K. Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.11. U.K. Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.12. U.K. Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.13. Spain Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.14. Spain Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.15. Spain Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.16. Russia Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.17. Russia Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.18. Russia Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.19. Rest of Europe Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.20. Rest of Europe Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.21. Rest of Europe Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 6.1.1. Large Molecule
    • 6.1.2. Small Molecule
  • 6.2. Asia Pacific Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Asia Pacific Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.3.1. Retail Pharmacies
    • 6.3.2. Hospital Pharmacies
    • 6.3.3. Online Pharmacies
  • 6.4. Asia Pacific Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.2. China Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.3. China Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.4. Japan Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.5. Japan Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.6. Japan Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.7. South Korea Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.8. South Korea Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.9. South Korea Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.10. India Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.11. India Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.12. India Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.13. Southeast Asia Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.14. Southeast Asia Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.15. Southeast Asia Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.16. Rest of SAO Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.17. Rest of SAO Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.18. Rest of SAO Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 7.1. Latin America Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 7.1.1. Large Molecule
    • 7.1.2. Small Molecule
  • 7.2. Latin America Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Latin America Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.3.1. Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Latin America Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 7.4.2. Brazil Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.3. Brazil Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.4. Mexico Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 7.4.5. Mexico Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.6. Mexico Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.7. Argentina Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 7.4.8. Argentina Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.9. Argentina Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.10. Rest of LATAM Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 7.4.11. Rest of LATAM Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.12. Rest of LATAM Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 8.1.1. Large Molecule
    • 8.1.2. Small Molecule
  • 8.2. Middle East & Africa Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Middle East & Africa Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Middle East & Africa Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.2. GCC Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.3. GCC Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.4. South Africa Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.5. South Africa Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.6. South Africa Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.7. Egypt Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.8. Egypt Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.9. Egypt Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.10. Nigeria Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.11. Nigeria Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.12. Nigeria Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.13. Rest of Middle East Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.14. Rest of Middle East Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.15. Rest of Middle East Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Teva Pharmaceutical Industries Ltd.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Sandoz Group AG
    • 9.4.3. Mylan N.V. (Viatris)
    • 9.4.4. Biocon
    • 9.4.5. Sun Pharmaceutical Industries Ltd.
    • 9.4.6. Lupin Pharmaceuticals
    • 9.4.7. Fresenius Kabi AG
    • 9.4.8. Pfizer Inc.
    • 9.4.9. Lupin Pharmaceuticals
    • 9.4.10. Zydus Cadila

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations